Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions

Next Previous
Trial Profile

Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Entrectinib (Primary)
  • Indications Colorectal cancer; Neuroblastoma; Non-small cell lung cancer; Solid tumours
  • Focus Expanded access; Therapeutic Use
  • Sponsors Ignyta

    • Most Recent Events

    • 04 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top